{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:21:34Z","timestamp":1793881294122,"version":"4.7.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["NS059600"],"award-info":[{"award-number":["NS059600"]}]},{"name":"Michael J. Fox Foundation and the Center for Development"},{"name":"Behavioral Neuroscience at Binghamton University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.neuropharm.2013.09.017","type":"journal-article","created":{"date-parts":[[2013,9,22]],"date-time":"2013-09-22T09:34:14Z","timestamp":1379842454000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats"],"prefix":"10.1016","volume":"77","author":[{"given":"Melissa M.","family":"Conti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne Y.","family":"Ostock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lindenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam A.","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Kampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich","family":"Dell'isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Katzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.09.017_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0304-3940(95)11817-G","article-title":"l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluoresence study","volume":"195","author":"Arai","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib2","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jiminez","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib3","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1523\/JNEUROSCI.22-15-06766.2002","article-title":"Serotonin clearance in\u00a0vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter","volume":"22","author":"Benmansour","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib4","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib5","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1460-9568.2012.08202.x","article-title":"Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats","volume":"36","author":"Bishop","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0893-133X(96)00242-4","article-title":"Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response","volume":"16","author":"Blier","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa- induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib8","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/jnr.21642","article-title":"Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model","volume":"86","author":"Branchi","year":"2008","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0091-3057(01)00701-8","article-title":"Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake; a pharmacological characterization of diverse classes of antidepressant agents","volume":"71","author":"Brocco","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-001-0986-x","article-title":"Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex","volume":"160","author":"Bymaster","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/sj.bjp.0701420","article-title":"The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain","volume":"122","author":"Casanovas","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","article-title":"Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions","volume":"88","author":"Chang","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib14","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/01.WNL.0000161841.41885.80","article-title":"Short-term paroxetine treatment does not alter the motor response to levodopa in PD","volume":"64","author":"Chung","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2008.10.004","article-title":"Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy","volume":"121","author":"Daws","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib16","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.45.10.1855","article-title":"Levodopa-induced dyskinesias are improved by fluoxetine","volume":"45","author":"Durif","year":"1995","journal-title":"Neurol"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.neubiorev.2010.06.007","article-title":"Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment","volume":"35","author":"Eskow-Jaunarajs","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of l-DOPA-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410270405","article-title":"Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease","volume":"27","author":"Halliday","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1254\/jphs.12003FP","article-title":"Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on l-DOPA-induced rotational behavior in a hemiparkinsonian rat model","volume":"119","author":"Inden","year":"2012","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib26","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib27","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/WNR.0b013e3283300fd7","article-title":"Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia","volume":"20","author":"Jaunarajs","year":"2009","journal-title":"NeuroReport"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2006.03.059","article-title":"Reuptake of l-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters","volume":"402","author":"Kannari","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","article-title":"Activation of 5-HT1A but not 5-HT1Breceptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib30","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/j.1471-4159.1986.tb08506.x","article-title":"A\u00a0semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation","volume":"46","author":"Kilpatrick","year":"1986","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.neuroscience.2012.07.064","article-title":"Distance from source of reward as a marker for extinction-induced \u201cdespair\u201d: modulation by the antidepressants clomipramine and citalopram","volume":"223","author":"Komorowski","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00213-007-1030-6","article-title":"The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram","volume":"197","author":"Kuan","year":"2008","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib33","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1523\/JNEUROSCI.0576-11.2011","article-title":"Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation","volume":"31","author":"Larsen","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1353-8020(99)00050-4","article-title":"Worsening of Parkinson's disease by citalopram","volume":"6","author":"Linazasoro","year":"2000","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0014-2999(95)00573-4","article-title":"Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in\u00a0vivo microdialysis study","volume":"286","author":"Malagi\u00e9","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","article-title":"Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1Breceptor agonists in the rat Parkinson model","volume":"219","author":"Mu\u00f1oz","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobio. Disord."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib40","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1034\/j.1600-0447.2001.00372.x","article-title":"Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study","volume":"104","author":"Nilsson","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of Sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin. Neuropharmacol"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib42","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","article-title":"Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study","volume":"67","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib43","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib44","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/0024-3205(92)90423-M","article-title":"Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum","volume":"50","author":"Perry","year":"1992","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib45","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/WNL.0b013e3181feb2ab","article-title":"Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures","volume":"75","author":"Politis","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/jpet.107.126219","article-title":"Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease","volume":"323","author":"Putterman","year":"2007","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002826-200201000-00004","article-title":"The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with l-Dopa","volume":"25","author":"Rampello","year":"2002","journal-title":"Clin. Neuropharmacol"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00702-007-0811-8","article-title":"Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline","volume":"115","author":"Speiser","year":"2008","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pbb.2005.06.013","article-title":"Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat","volume":"81","author":"Taylor","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib51","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pbb.2009.05.011","article-title":"Antidepressant-like effects of paroxetine are produced by lower doses than those with produce nausea","volume":"93","author":"Tuerke","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.09.017_bib52","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/00001756-200105080-00015","article-title":"Fluoxetine reduces l-DOPA-derived extracellular DA in the 6-hydroxydopamine-lesioned rat striatum","volume":"12","author":"Yamato","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2013.09.017_bib53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neuron.2005.02.010","article-title":"Corelease of dopamine and serotonin from striatal dopamine terminals","volume":"46","author":"Zhuo","year":"2005","journal-title":"Neuron"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T07:44:05Z","timestamp":1563954245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813004243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":53,"alternative-id":["S0028390813004243"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.09.017","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}